title: Plasma concentrations of three methylated arginines, endogenous nitric oxide synthase inhibitors, in schizophrenic patients undergoing antipsychotic drug treatment.
abstract: Plasma concentration of three methylated arginines, endogenous nitric oxide synthase inhibitors, is not studied in schizophrenic patients. The purpose of this study was to determine plasma concentrations of N(G)-monomethyl-L-arginine (l-NMMA), N(G),N(G)-dimethyl-L-arginine (ADMA), N(G),N(G')-dimethyl-L-arginine (SDMA), and l-arginine in 56 male and 45 female schizophrenic patients undergoing antipsychotic drug treatment versus those of 39 male and 24 female healthy controls. Plasma concentrations of methylated arginines and l-arginine were measured using newly developed high performance liquid chromatography with fluorescence detection which we previously reported. Methylated arginine levels were slightly but significantly higher in schizophrenic patients. L-Arginine levels and the l-arginine/(ADMA+l-NMMA) ratio were higher in schizophrenic patients than in healthy controls. It is considered that pharmacological treatment of schizophrenic patients may lower methylated arginine levels that are increased by the disease, and increase L-arginine levels, eliciting an improvement in nitric oxide (NO) bioavailability.
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan; Pfizer Worldwide Research & Development, Tokyo Laboratories, Tokyo, Japan.
authors.forename: Satoko
authors.initials: S
authors.lastname: Nonaka-Hashida
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
authors.forename: Masae
authors.initials: M
authors.lastname: Sekine
authors.affiliation: Department of Psychiatry Dokkyo Medical University School of Medicine, Tochigi, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ozeki
authors.affiliation: Department of Psychiatry Dokkyo Medical University School of Medicine, Tochigi, Japan.
authors.forename: Kumiko
authors.initials: K
authors.lastname: Fujii
authors.affiliation: Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University School of Medicine, Tochigi, Japan.
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Akiyama
authors.affiliation: Department of Psychiatry Dokkyo Medical University School of Medicine, Tochigi, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Shimoda
authors.affiliation: Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Tsunoda
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
authors.forename: Masumi
authors.initials: M
authors.lastname: Katane
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Saitoh
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Miyamoto
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan. Electronic address: hommah@pharm.kitasato-u.ac.jp.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Homma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult; D019323:omega-N-Methylarginine / Q000097:blood
chemical_list: D014150:Antipsychotic Agents; C000598073:N(G),N(G')-dimethylarginine; D019323:omega-N-Methylarginine; C018524:N,N-dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase
keywords: ADMA; L-NMMA; L-arginine; NOS inhibitor; SDMA; Schizophrenia